Naftopidil dihydrochloride is used as a selective antagonist of 5-HT1A and α1-adrenergic receptors; it exhibits antiproliferative effects in both androgen-sensitive and androgen-insensitive human prostate cancer cell lines by inducing G1 cell cycle arrest; it inhibits prostate cancer tumor growth in vivo; it increases bladder capacity and suppresses rhythmic bladder contractions by inhibiting afferent nerve activity; it effectively alleviates enuresis with greater potency than tamsulosin; it reduces prostate pressure induced by phenylephrine selectively without significantly affecting mean arterial blood pressure.